Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 10/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.43 |
| ▸ | OTUD7B | Q6GQQ9 | 2/20 | 0.41 |
| ▸ | BACE1 | P56817 | 1/20 | 0.40 |
| ▸ | HTR2C | P28335 | 2/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.40 |
| ▸ | FABP4 | P15090 | 1/20 | 0.39 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.38 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4127461 | 0.89 | HTR2C (0.51) | HRH3HTR2CHTR2A | |
| SCHEMBL4136470 | 0.88 | HRH3 (0.47) | HRH3CYP2D6BACE1 | |
| SCHEMBL4135788 | 0.87 | HRH3 (0.51) | HRH3CYP2D6OTUD7BBACE1 | |
| SCHEMBL4142012 | 0.86 | PDK1 (0.43) | HRH3CYP2D6HTR2CHTR2A | |
| SCHEMBL4141225 | 0.85 | HRH3 (0.49) | HRH3CYP2D6BACE1HTR2C | |
| SCHEMBL4142009 | 0.85 | HRH3 (0.48) | HRH3CYP2D6BACE1 | |
| SCHEMBL4144748 | 0.85 | HRH3 (0.49) | HRH3CYP2D6OTUD7BBACE1HTR2C | |
| SCHEMBL4148990 | 0.84 | HRH3 (0.36) | HRH3BACE1HTR2CHTR2A | |
| SCHEMBL4766770 | 0.82 | S1PR1 (0.45) | HRH3HTR2CHTR2A | |
| SCHEMBL4135556 | 0.81 | CD274 (0.38) | HRH3HTR2CHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090163482-A1 | TETRALINES ANTAGONISTS OF THE H-3 RECEPTOR | MCHARDY STANTON FURST | 2009-06-25 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163482-A1 | TETRALINES ANTAGONISTS OF THE H-3 RECEPTOR | HRH3, HRH4, HRH1 | HRH3 1/4885CYP2D6 1777/4885OTUD7B 1717/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.